GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Shares Outstanding (EOP)

Australian Clinical Labs (ASX:ACL) Shares Outstanding (EOP) : 199.1 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Australian Clinical Labs's shares outstanding for the quarter that ended in Dec. 2024 was 199.1 Mil.

Australian Clinical Labs's quarterly shares outstanding declined from Jun. 2024 (201.8 Mil) to Dec. 2024 (199.1 Mil). It means Australian Clinical Labs bought back shares from Jun. 2024 to Dec. 2024 .

Australian Clinical Labs's annual shares outstanding stayed the same from Jun. 2023 (201.8 Mil) to Jun. 2024 (201.8 Mil).


Australian Clinical Labs Shares Outstanding (EOP) Historical Data

The historical data trend for Australian Clinical Labs's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Shares Outstanding (EOP) Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24
Shares Outstanding (EOP)
- 201.83 201.83 201.83 201.83

Australian Clinical Labs Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only 200.50 201.83 200.50 201.83 199.13

Competitive Comparison of Australian Clinical Labs's Shares Outstanding (EOP)

For the Diagnostics & Research subindustry, Australian Clinical Labs's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australian Clinical Labs's Shares Outstanding (EOP) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Shares Outstanding (EOP) falls into.


;
;

Australian Clinical Labs Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Australian Clinical Labs  (ASX:ACL) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Australian Clinical Labs Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines